Explorative Trial to Investigate the Safety and Clinical Effects of Autologous Mesenchymal Bone Marrow Stem Cells (MSC) Following Their Intrathecal and Intravenous Administration in Severe Cases of Multiple Sclerosis (MS)
Explorative Trial to Investigate the Safety and Clinical Effects of Autologous Mesenchymal Bone Marrow Stem Cells (MSC) Following Their Intrathecal and Intravenous Administration in Severe Cases of Multiple Sclerosis (MS) is a PHASE1 clinical asset sponsored by Hadassah Medical Organization in Multiple Sclerosis. SEO and diligence focus: Injection of autologous bone marrow derived mesenchymal stem cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Multiple Sclerosis
Modality: protein therapy
Target: Injection of autologous bone marrow derived mesenchymal stem cells
Sponsor: Hadassah Medical Organization
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Injection of autologous bone marrow derived mesenchymal stem cells
View original source fields
Condition raw: Multiple Sclerosis
Condition normalized: Multiple Sclerosis
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Injection of autologous bone marrow derived mesenchymal stem cells
Target normalized: Injection of autologous bone marrow derived mesenchymal stem cells